Nuvessa is a branded, prescription metronidazole vaginal gel 1.3% indicated for bacterial vaginosis in females aged 12 years and older, with a single-dose prefilled applicator presentation. This precise identity distinguishes it from ordinary 0.75% vaginal metronidazole gels, from oral Flagyl products, and from MetroGel skin products. The percentage cannot be treated as a minor packaging variant because formulation and labeled administration are different.
Nuvessa is often discussed alongside Vandazole and generic vaginal metronidazole products. Importantly, the claim that Nuvessa has no FDA-approved generic is outdated: FDA approved Encube Ethicals' ANDA 216795 for metronidazole vaginal gel 1.3% in March 2024, and a corresponding DailyMed generic label is available. Regulatory approval does not guarantee a particular pharmacy currently has either brand or generic stock; it does establish that the generic category cannot be dismissed as nonexistent.
This brand page focuses on the Nuvessa 1.3% product, its single-dose applicator, exact generic status and pharmacy verification. General BV management belongs to the BV overview; head-to-head formulation decisions belong to Nuvessa versus Vandazole. A valid prescription and professional assessment remain necessary regardless of brand or generic availability.
The Nuvessa label identifies 65 mg of metronidazole in 5 g of gel, a 1.3% concentration, packaged as a prefilled vaginal applicator. The labeled administration is a single intravaginal dose at bedtime; this description identifies the approved product rather than advising treatment without a prescription. Nuvessa is not meant for oral ingestion, skin use or ophthalmic use.
This combination of route, concentration and delivery system makes the product distinct. A pharmacy search showing only 'metronidazole gel' omits information needed for a correct match. The intended patient population and labeled indication are also important: Nuvessa is indicated for BV in females aged 12 and older. The clinician decides whether it is appropriate for an individual.
| Vaginal product | Concentration and presentation | Verification question |
|---|---|---|
| Nuvessa brand | 1.3% gel, single-dose prefilled applicator | Does the prescription identify this exact 1.3% product? |
| FDA-approved 1.3% generic | 1.3% gel, product-specific prefilled applicator | Is the offered ANDA-approved product appropriate under the prescription? |
| Vandazole | 0.75% vaginal gel | Do not treat a different concentration and regimen as equivalent |
| Generic 0.75% vaginal gel | 0.75% vaginal dosage form | Verify the separate reference product and labeled instructions |
The FDA issued approval for Encube Ethicals' metronidazole vaginal gel 1.3% abbreviated application ANDA 216795 on March 18, 2024. The approval letter describes therapeutic equivalence to the Nuvessa reference listed drug, subject to the relevant regulatory requirements. DailyMed also carries 1.3% metronidazole vaginal-gel labeling for Encube, making the generic product publicly identifiable.
There is a difference between an approved product and an item a specific pharmacy can order today. Patent information, commercial distribution, insurance lists and wholesaler inventory can affect the real-world answer without changing the underlying FDA approval record. A blanket 'no Nuvessa generic' statement is inaccurate; a blanket promise of affordable generic supply would be equally unsupported.
ANDA 216795 identifies an approved 1.3% generic referencing NUVESSA; the equivalent drug-and-device presentation matters because the reference brand uses a prefilled vaginal applicator. Approval does not establish that a named wholesaler carries the generic today. When comparing a brand request and a proposed generic, the pharmacist should match the product application, concentration and administration device before addressing coverage or stock.
Nuvessa is designed as a single-dose vaginal presentation with a prefilled applicator. This feature affects package recognition, prescription directions and the amount of product dispensed. It should not be interpreted as evidence that all vaginal metronidazole products are administered once or that patients can combine multiple 0.75% gel applicators to make a 1.3% product.
A clinician-selected regimen reflects diagnosis, evidence, labeled formulation and patient-specific factors. The appropriate use of a different brand or generic must be confirmed professionally. Product packaging should be checked for prefilled components, expiry and the correct route, especially when the prescription and online image do not match.
Bacterial vaginosis is diagnosed through clinical context and, when appropriate, examination or testing. Nuvessa labeling concerns BV, but symptoms such as odor, discharge or irritation are not uniquely diagnostic. Other infections can require different therapies, and using Nuvessa for a self-diagnosed condition may delay appropriate evaluation.
The CDC lists metronidazole 1.3% vaginal gel as an additional BV regimen while distinguishing its place from other recommended regimens. Those guidelines are not a shopping recommendation or permission to use a stored prescription for new symptoms. The treating professional weighs patient history, recurrent episodes and other causes of symptoms when selecting therapy.
A simple percentage comparison misses the product difference: Nuvessa is 1.3% in a single-dose prefilled applicator, while Vandazole is 0.75% vaginal gel with a different labeled treatment framework. Both are vaginal metronidazole, but a pharmacist cannot automatically treat these as the same prescription. The package and regimen are part of product identity, not optional extras.
If a pharmacy proposes a change because of coverage or supply, ask whether the clinician approved the alternate formulation. The dedicated Nuvessa–Vandazole comparison explains this decision in greater depth without turning the brand page into a duplicate commercial comparison.
A prescriber may determine that Nuvessa is appropriate after evaluating BV symptoms, medical history and relevant considerations. A pharmacy checks the resulting valid prescription, clarifies whether the product must be branded, and identifies an approved supply matching the intended 1.3% presentation. A request for 0.75% generic gel should not be assumed to be a request for this single-dose product.
For remote care, consultation and dispensing are distinct steps. A telehealth visit does not guarantee a prescription, and a pharmacy listing does not establish stock. Use vaginal telehealth evaluation guidance to understand the clinical workflow and vaginal gel online pharmacy safeguards for seller checks.
NUVESSA is locally administered but still has product-specific contraindications and interaction cautions. Its U.S. label identifies hypersensitivity to metronidazole, other nitroimidazoles, parabens or other formulation ingredients; it also says not to use NUVESSA concurrently with disulfiram or within two weeks of its use. A pharmacist or clinician should review the actual medicine list and prior reactions rather than treating one intravaginal administration as free from medication interactions.
NUVESSA labeling also instructs patients to avoid ethanol or propylene glycol during treatment and for at least 24 hours afterward; this is a product-label precaution, not a substitute for individualized advice or a general statement about every metronidazole formulation. Pregnancy and lactation questions need a clinician-led discussion of the current label. Unexpected reactions, severe symptoms and recurring BV complaints require assessment rather than repeating a stored prescription.
A reliable verification uses both DailyMed and FDA approval records. First, identify the exact Nuvessa brand label, route, concentration and prefilled applicator. Then confirm the relevant 1.3% generic application, if offered, rather than assuming any similarly titled metronidazole gel qualifies. Marketing labels can be revised, and product records may not be updated in lockstep with individual pharmacies' systems.
FDA's Orange Book helps confirm application and therapeutic-equivalence context. When an online seller markets a product simply as 'generic Nuvessa 0.75%,' the contradictory concentration should prompt clarification. A genuine 1.3% generic is not the same product category as generic 0.75% vaginal gel.
Costs depend on the dispensed product, insurance formulary, pharmacy and quantity. A quote for 0.75% generic metronidazole gel may be cheaper or more visible in search results, but it is not a quote for the 1.3% Nuvessa prescription. Brand-versus-generic cost comparisons should therefore use matching route, strength and package details.
Use Nuvessa price and insurance factors for a focused, evergreen cost review. Do not assume a generic approval creates immediate pharmacy supply, an automatic copay reduction or eligibility for a particular savings program.
Verify that the order is for vaginal metronidazole 1.3%, that the product is Nuvessa or an authorized equivalent under the prescription, and that the package matches a prefilled single-dose applicator. Check the product's current instructions with the pharmacist. If a 0.75% item is substituted in a shopping cart, stop and request professional clarification.
Confirm pharmacy licensing, prescription verification and access to a pharmacist before payment. Finally, distinguish a regulatory product listing from verified stock and a general coupon page from an actual final patient cost. These checks help ensure the correct medicine is dispensed without promising treatment or supply.
Nuvessa is a branded prescription metronidazole vaginal gel 1.3% provided as a single-dose prefilled applicator for bacterial vaginosis.
NUVESSA is labeled for bacterial vaginosis in females aged 12 years and older. The label does not establish safety or efficacy in younger children. A clinician must determine whether an individual needs examination, testing and this prescription.
Yes. FDA approved an Encube Ethicals metronidazole vaginal gel 1.3% ANDA in March 2024. Approval does not guarantee local stock.
No. Nuvessa is a 1.3% single-dose product. Generic 0.75% vaginal gels belong to a different formulation and prescription category.
No. Nuvessa is formulated and labeled for vaginal administration, not topical skin treatment.
Nuvessa is labeled for BV, and intravaginal gel should not be substituted for clinically indicated systemic treatment of trichomoniasis.
No. It is a U.S. prescription medicine.
Nuvessa is a 1.3% single-dose prefilled applicator; Vandazole is 0.75% vaginal gel with different labeled presentation and directions.
No. Regulatory approval and labeling provide product information, not real-time inventory or a guaranteed quote.
Do not change concentrations or regimens yourself. The prescriber and pharmacist should determine any appropriate replacement.